Subgroup analyses of diffuse large B-cell lymphoma and indolent lymphoma cohorts from a phase IIa study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkin's lymphoma (R-R NHL)

被引：0
|
作者：
Buske, C. [1 ]
Jurczak, W. [2 ]
Zinzani, P. L. [3 ]
Gaidano, G. [4 ]
Goy, A. [5 ]
Provencio, M. [6 ]
Nagy, Z. [7 ]
Robak, T. [8 ]
Maddocks, K. [9 ]
Ambarkhane, S. [10 ]
Winderlich, M. [10 ]
Endell, J. [10 ]
Blum, K. A. [9 ]
机构：
[1] Univ Hosp Ulm, Inst Expt Canc Res, Comprehens Canc Ctr Ulm, Ulm, Germany
[2] Jagiellonian Univ, Dept Hematol, Krakow, Poland
[3] Univ Bologna, Inst Hematol L&A Seragnoli, Bologna, Italy
[4] Amedeo Avogadro Univ Eastern Piedmont, Div Hematol, Dept Translat Med, Novara, Italy
[5] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[6] Univ Hosp Puerta De Hierro, Dept Med Oncol, Madrid, Spain
[7] Semmelweis Univ, Dept Internal Med 1, Budapest, Hungary
[8] Med Univ Lodz, Dept Hematol, Lodz, Poland
[9] Ohio State Univ, Ctr Comprehens Canc, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA
[10] MorphoSys AG, Martinsried, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P246
引用
收藏
页码：72 / 72
页数：1
相关论文
共 50 条
  • [1] Subgroup analyses of diffuse large B-cell lymphoma (DLBCL) and indolent lymphoma cohorts from a phase Ha study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkin's lymphoma (R-R NHL).
    Jurczak, Wojciech
    Zinzani, Pier Luigi
    Gaidano, Gianluca
    Goy, Andre
    Provencio, Mariano
    Nagy, Zsolt
    Robak, Tadeusz
    Maddocks, Kamij.
    Buske, Christian
    Ambarkhane, Sumeet Vijay
    Winderlich, Mark
    Endell, Jan
    Blum, Kristie A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] SUBGROUP ANALYSES OF DIFFUSE LARGE B-CELL LYMPHOMA AND INDOLENT LYMPHOMA COHORTS FROM A PHASE IIA STUDY OF SINGLE-AGENT MOR208 IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN'S LYMPHOMA
    Jurczak, W.
    Zinzani, P. L.
    Gaidano, G.
    Goy, A.
    Provencio, M.
    Nagy, Z.
    Robak, T.
    Maddocks, K.
    Buske, C.
    Ambarkhane, S.
    Winderlich, M.
    Endell, J.
    Blum, K.
    HAEMATOLOGICA, 2016, 101 : 317 - 317
  • [3] Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study
    Jurczak, Wojciech
    Zinzani, Pier Luigi
    Gaidano, Gianluca
    Goy, Andre
    Provencio, Mariano
    Nagy, Zsolt
    Robak, Tadeusz
    Maddocks, Kami J.
    Buske, Christian
    Ambarkhane, Sumeet
    Winderlich, Mark
    Dirnberger-Hertweck, Maren
    Endell, Jan
    Blum, Kristie A.
    BLOOD, 2016, 128 (22)
  • [4] Phase IIa study of single-agent MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
    Jurczak, Wojciech
    Zinzani, Pier Luigi
    Goy, Andre
    Provencio, Mariano
    Nagy, Zsolt
    Robak, Tadeusz
    Maddocks, Kami J.
    Buske, Christian
    Korolkiewicz, Roman
    Winderlich, Mark
    Blum, Kristie A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Phase IIa Study of Single-Agent MOR208 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
    Jurczak, Wojciech
    Zinzani, Pier Luigi
    Gaidano, Gianluca
    Goy, Andre
    Provencio, Mariano
    Nagy, Zsolt
    Robak, Tadeusz
    Maddocks, Kami J.
    Buske, Christian
    Korolkiewicz, Roman Pawel
    Striebel, Frank
    Blum, Kristie
    BLOOD, 2015, 126 (23)
  • [6] Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma
    Jurczak, W.
    Zinzani, P. L.
    Gaidano, G.
    Goy, A.
    Provencio, M.
    Nagy, Z.
    Robak, T.
    Maddocks, K.
    Buske, C.
    Ambarkhane, S.
    Winderlich, M.
    Dirnberger-Hertweck, M.
    Korolkiewicz, R.
    Blum, K. A.
    ANNALS OF ONCOLOGY, 2018, 29 (05) : 1266 - 1272
  • [7] L-MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R-R DLBCL)-A SINGLE-ARM PHASE II STUDY
    Maddocks, K.
    Gonzalez Barca, E.
    Jurczak, W.
    Liberati, A. M.
    Duell, J.
    Nagy, Z.
    Papaj-K, T.
    Andre, M.
    Kalakonda, N.
    Dreyling, M.
    Zinzani, P. L.
    Ambarkhane, S.
    Weirather, J.
    Salles, G.
    HAEMATOLOGICA, 2017, 102 : 174 - 174
  • [8] L-MIND: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R-R DLBCL) - a single-arm phase II study
    Duell, J.
    Gonzalez Barca, E.
    Liberati, A. M.
    Salles, G.
    Gaidano, G.
    Jurczak, W.
    Nagy, Z.
    Papajlk, T.
    Andre, M.
    Zinzani, P. L.
    Kalakonda, N.
    Ambarkhane, S.
    Weirather, J.
    Maddocks, K.
    Dreyling, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 68 - 68
  • [9] A PHASE IIA STUDY OF SINGLE- AGENT MOR208, AN FC-OPTIMIZED ANTI-CD19 ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA
    Jurczak, W.
    Zinzani, P. L.
    Goy, A.
    Provencio, M.
    Nagy, Z.
    Robak, T.
    Maddocks, K.
    Buske, C.
    Korolkiewicz, R.
    Winderlich, M.
    Blum, K.
    HAEMATOLOGICA, 2015, 100 : 395 - 396
  • [10] Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Duell, Johannes
    Maddocks, Kami J.
    Gonzalez-Barca, Eva
    Jurczak, Wojciech
    Liberati, Anna Marina
    de Vos, Sven
    Nagy, Zsolt
    Obr, Ales
    Gaidano, Gianluca
    Abrisqueta, Pau
    Andre, Marc
    Dreyling, Martin
    Menne, Tobias F.
    Dirnberger-Hertweck, Maren
    Weirather, Johannes
    Ambarkhane, Sumeet
    Salles, Gilles A.
    BLOOD, 2019, 134
12345